Keith Crandell's Net Worth

$2.3 Billion

Who is Keith Crandell?

Keith Crandell has an estimated net worth of $2.3 Billion. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., KYTHERA BIOPHARMACEUTICALS INC, ALNYLAM PHARMACEUTICALS INC, PHASERX, INC., APROPOS TECHNOLOGY INC, Neumora Therapeutics, Inc., Lyell Immunopharma, Inc., ADESTO TECHNOLOGIES Corp, IMPINJ INC, AGIOS PHARMACEUTICALS INC, NeurogesX Inc, VBI VACCINES INC., Receptos, Inc., CELEBRATE EXPRESS, INC., DA32 Life Science Tech Acquisition Corp., Gossamer Bio, Inc., Scholar Rock Holding Corp, Erasca, Inc., 908 Devices Inc., Pulmatrix, Inc., Karuna Therapeutics, Inc., Quanterix Corp, Verve Therapeutics, Inc., bluebird bio, Inc., Denali Therapeutics Inc., FATE THERAPEUTICS INC, Twist Bioscience Corp, Sage Therapeutics, Inc., Vir Biotechnology, Inc., Beam Therapeutics Inc., Metacrine, Inc., Bellerophon Therapeutics, Inc., XCYTE THERAPIES INC, Unity Biotechnology, Inc., Syros Pharmaceuticals, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., Juno Therapeutics, Inc., Homology Medicines, Inc., ILLUMINA INC, Prime Medicine, Inc., Achaogen Inc, XTERA COMMUNICATIONS, INC., and Trubion Pharmaceuticals, Inc.

SEC CIK

Keith Crandell's CIK is 0001219039

Past Insider Trading and Trends

2021 was Keith Crandell's most active year for acquiring shares with 75 total transactions. Keith Crandell's most active month to acquire stocks was the month of September. 2021 was Keith Crandell's most active year for disposing of shares, totalling 86 transactions. Keith Crandell's most active month to dispose stocks was the month of April. 2023 saw Keith Crandell paying a total of $31,456,134.18 for 19,486,996 shares, this is the most they've acquired in one year. In 2020 Keith Crandell cashed out on 46,808,081 shares for a total of $7,755,000.00, their largest year based on trade value.